PLoS Neglected Tropical Diseases (Oct 2016)

Full Genome Sequence and sfRNA Interferon Antagonist Activity of Zika Virus from Recife, Brazil.

  • Claire L Donald,
  • Benjamin Brennan,
  • Stephanie L Cumberworth,
  • Veronica V Rezelj,
  • Jordan J Clark,
  • Marli T Cordeiro,
  • Rafael Freitas de Oliveira França,
  • Lindomar J Pena,
  • Gavin S Wilkie,
  • Ana Da Silva Filipe,
  • Christopher Davis,
  • Joseph Hughes,
  • Margus Varjak,
  • Martin Selinger,
  • Luíza Zuvanov,
  • Ania M Owsianka,
  • Arvind H Patel,
  • John McLauchlan,
  • Brett D Lindenbach,
  • Gamou Fall,
  • Amadou A Sall,
  • Roman Biek,
  • Jan Rehwinkel,
  • Esther Schnettler,
  • Alain Kohl

DOI
https://doi.org/10.1371/journal.pntd.0005048
Journal volume & issue
Vol. 10, no. 10
p. e0005048

Abstract

Read online

BackgroundThe outbreak of Zika virus (ZIKV) in the Americas has transformed a previously obscure mosquito-transmitted arbovirus of the Flaviviridae family into a major public health concern. Little is currently known about the evolution and biology of ZIKV and the factors that contribute to the associated pathogenesis. Determining genomic sequences of clinical viral isolates and characterization of elements within these are an important prerequisite to advance our understanding of viral replicative processes and virus-host interactions.Methodology/principal findingsWe obtained a ZIKV isolate from a patient who presented with classical ZIKV-associated symptoms, and used high throughput sequencing and other molecular biology approaches to determine its full genome sequence, including non-coding regions. Genome regions were characterized and compared to the sequences of other isolates where available. Furthermore, we identified a subgenomic flavivirus RNA (sfRNA) in ZIKV-infected cells that has antagonist activity against RIG-I induced type I interferon induction, with a lesser effect on MDA-5 mediated action.Conclusions/significanceThe full-length genome sequence including non-coding regions of a South American ZIKV isolate from a patient with classical symptoms will support efforts to develop genetic tools for this virus. Detection of sfRNA that counteracts interferon responses is likely to be important for further understanding of pathogenesis and virus-host interactions.